Imunon (IMNN) Depreciation & Amortization (CF) (2010 - 2026)
Imunon's (IMNN) quarterly Depreciation & Amortization (CF) came in at $70000.0 in Q1 2026, up 4.98% YoY from $66681.0 in Q1 2025, and down 6.88% on a QoQ basis from $75170.0 in Q4 2025.
Imunon (IMNN) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Imunon (IMNN) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $70000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 4.98% year-over-year to $70000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $295319.0 (up 24.84% YoY) and the FY2025 annual result came in at $407000.0, down 14.85% from the prior year.
- Depreciation & Amortization (CF) declined to $70000.0 in Q1 2026, from $75170.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $192678.0 in Q1 2023 to a low of -$316552.0 in Q4 2022.
- A 5-year average of $70029.0 and a median of $70301.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 297.63% — and 2023, when it surged 122.63%.
- Tracing IMNN's Depreciation & Amortization (CF) over 5 years: stood at -$316552.0 in 2022, then surged by 122.63% to $71645.0 in 2023, then slumped by 48.03% to $37237.0 in 2024, then soared by 101.87% to $75170.0 in 2025, then fell by 6.88% to $70000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $70000.0 (Q1 2026), $75170.0 (Q4 2025), and $75140.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70,000.00 |
| Jun 30, 2026 | 70,000.00 |
| Mar 31, 2026 | 70,000.00 |
| Mar 31, 2026 | 70,000.00 |
| Dec 31, 2025 | 75,170.00 |
| Dec 31, 2025 | 75,170.00 |
| Sep 30, 2025 | 75,140.00 |
| Sep 30, 2025 | 75,140.00 |
| Jun 30, 2025 | 75,009.00 |
| Jun 30, 2025 | 75,009.00 |
| Mar 31, 2025 | 66,681.00 |
| Mar 31, 2025 | 66,681.00 |
| Dec 31, 2024 | 37,237.00 |
| Dec 31, 2024 | 37,237.00 |
| Sep 30, 2024 | 64,305.00 |
| Sep 30, 2024 | 64,305.00 |
| Jun 30, 2024 | 68,332.00 |
| Jun 30, 2024 | 68,332.00 |
| Mar 31, 2024 | 70,301.00 |
| Mar 31, 2024 | 70,301.00 |